While HER2DX has been previously validated in diverse early-stage HER2+ breast cancer populations, this study aimed to evaluate its prognostic and predictive performance in a randomized trial focused exclusively on older patients aged 70–80 years. Here, ERBB2 is linked to breast carcinoma.